Conference Coverage

TAVR cerebral protection device appears safe, effective

Publish date: June 7, 2016

 

AT EUROPCR 2016

References

Dr. Lansky replied that the much larger ongoing pivotal randomized, phase III REFLECT trial should provide definitive answers.

She reported receiving institutional research grant support from Keystone Heart, which produces the TriGuard device.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Prasugrel beats clopidogrel for complex PCI in ACS
MDedge Cardiology
CT renders transesophageal echo largely avoidable in TAVR
MDedge Cardiology
Prior pregnancy protects against TAVR complications
MDedge Cardiology
Cangrelor offers advantages for antiplatelet management in PCI
MDedge Cardiology
TAVR degeneration estimated at 50% after 8 years
MDedge Cardiology
Obesity paradox extends to TAVR but not SAVR
MDedge Cardiology
Pulmonary function testing adds little to STS risk scores
MDedge Cardiology
Point/Counterpoint: What’s best for chronic dissection: TEVAR or open?
MDedge Cardiology
Transcatheter aortic valve implantation equivalent to surgical replacement
MDedge Cardiology
Low hematocrit in elderly portends increased bleeding post PCI
MDedge Cardiology